Skip to main content
profile image
Selected Works of Philip Mease, MD
Article
O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials
Rheumatology (2016)
  • Dafna D. Gladman, Toronto Western Hospital
  • Arthur Kavanaugh, University of California, San Diego
  • Adewale O. Adebajo, University of Sheffield
  • Juan J. Gomez-Reino, University of Santiago de Compostela
  • Jürgen Wollenhaupt, Hochschule Hannover
  • Maurizio Cutolo, University of Genoa
  • Georg Schett, University of Erlangen-Nuremberg
  • Eric Lespessailles, University of Orléans
  • Melissa McIlraith, Celgene
  • ChiaChi Hu, Celgene
  • Christopher J. Edwards, University of Southampton
  • Charles A. Birbara, University of Massachusetts Medical School
  • Philip J. Mease, University of Washington
Link
Disciplines
Publication Date
April 1, 2016
DOI
10.1093/rheumatology/kew122.002
Citation Information
Dafna D. Gladman, Arthur Kavanaugh, Adewale O. Adebajo, Juan J. Gomez-Reino, et al.. "O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials" Rheumatology Vol. 55 (2016)
Available at: http://works.bepress.com/philip-mease/84/